Shares of Pfizer Inc. closed lower on Friday, shedding approximately 1% to finish at $26.60, as investors weighed competitive developments in the respiratory syncytial virus (RSV) vaccine market against positive news for the company's established blood-thinning therapy. The stock traded near its daily low, reflecting broader market weakness and ongoing questions about the pharmaceutical giant's growth trajectory in the coming years.
GSK Narrows RSV Competitive Edge
The downward pressure followed an announcement from rival GSK that the U.S. Food and Drug Administration (FDA) had expanded the label for its Arexvy vaccine. The regulatory nod now includes adults aged 18 to 49 who are at increased risk for severe RSV disease. This move directly challenges Pfizer's Abrysvo, which received FDA approval in October 2024 for adults 18 to 59 at higher risk. However, the Centers for Disease Control and Prevention (CDC) currently recommends Abrysvo only for individuals 75 and older, plus those aged 50 to 74 with certain vulnerabilities. GSK noted that its expanded label's practical use in the younger 18-to-49 cohort is contingent on a future update to CDC guidance.
Eliquis Data Offsets Some Pressure
Providing a counterbalance, new clinical data highlighted the efficacy of Pfizer's blockbuster blood thinner Eliquis, which it co-markets with Bristol Myers Squibb. A study published in The New England Journal of Medicine indicated that Eliquis was associated with clinically significant bleeding in 3.3% of patients with acute venous thrombosis, compared to 7.1% for Johnson & Johnson's Xarelto. The rates of recurrent blood clots showed no statistically significant difference between the two treatments. This favorable safety profile for Eliquis helped mitigate some of the negative sentiment stemming from the RSV competitive news.
Broader Market and Growth Context
The decline occurred against a backdrop of general market softness on Friday, with major indices finishing in negative territory. Stubbornly elevated oil prices and geopolitical tensions contributed to investor unease, putting additional scrutiny on companies like Pfizer whose significant growth catalysts may be several years away. Pfizer's leadership has been working to articulate a post-pandemic growth narrative after a steep decline in COVID-related product sales. In December, management provided 2026 revenue guidance in the range of $59.5 billion to $62.5 billion, with adjusted earnings per share projected between $2.80 and $3.00. This outlook factors in the anticipated drop in COVID sales and approximately $1.5 billion in revenue lost to patent expirations.
Leadership Maintains Turnaround Focus
During the company's 2025 annual review held on Thursday, Chief Executive Officer Albert Bourla reiterated the company's commitment to improving operational efficiency. He pointed to ongoing efforts to streamline the organization, highlighting "improved productivity and margins" as a buffer against softer revenue. This focus on cost reduction has been a consistent theme from Pfizer's leadership as it navigates a transitional period.
Analyst Views Remain Mixed
Wall Street analysts offer divergent perspectives on the stock's near-term potential. In December, an analyst from JPMorgan suggested there could be "modest EPS upside through the year" if the company's cost-cutting initiatives remain on track. Conversely, an analyst from Bernstein indicated that the shares are unlikely to "break out of its current mid-$20s price range" until investors gain greater clarity on sustainable growth drivers. Pfizer's closing price on Friday placed it squarely within that described range.
Long-Term Outlook Requires Patience
The near-to-medium-term picture for Pfizer appears complex. The company does not anticipate a return to revenue growth before 2029. In January, CEO Bourla cautioned that the path would remain "choppy," citing headwinds from patent cliffs, the continued decline of COVID product sales, and pricing pressures from government healthcare programs. With a market capitalization hovering around $135 billion, the stock's valuation suggests the market is awaiting more concrete evidence of a successful turnaround before committing more capital.
